---
title: "U.S. stock market update: Vor BioPharma up 9.02%"
description: "Vor BioPharma rose 9.02%; AbbVie rose 2.30%, with a transaction volume of 200 million USD; Viking Therapeutics rose 5.28%, with a transaction volume of 199 million USD; Gilead Sciences rose 1.67%, wit"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/253840683.md"
published_at: "2025-08-20T14:12:58.000Z"
---

# U.S. stock market update: Vor BioPharma up 9.02%

> Vor BioPharma rose 9.02%; AbbVie rose 2.30%, with a transaction volume of 200 million USD; Viking Therapeutics rose 5.28%, with a transaction volume of 199 million USD; Gilead Sciences rose 1.67%, with a transaction volume of 117 million USD; Amgen rose 1.38%, with a market capitalization of 161.4 billion USD

**U.S. Stock Market Midday Update**

Vor BioPharma, up 9.02%, with increased trading volume. Based on recent key news:

1.  On August 18, Vor Bio announced the grant of inducement stock options and restricted stock units under Nasdaq listing rule 5635(c)(4) to incentivize new employees. This news boosted market confidence, leading to a 9.02% increase in stock price.
    
2.  On August 18, Vor Bio released a press release detailing the grants of the aforementioned stock options and restricted stock units, further enhancing investor confidence.
    
3.  On August 18, Vor Bio's board compensation committee approved these grants during the period from August 4 to August 18, demonstrating the company's proactive measures to attract and retain talent, driving the stock price up.
    

**Stocks with High Trading Volume in the Industry**

AbbVie, up 2.30%, with increased trading volume. Based on recent important news:

1.  On August 19, AbbVie completed its acquisition of Capstan Therapeutics, with a transaction value of up to $2.1 billion, driving the stock price up 2.3%.
    
2.  On August 18, AbbVie's high dividend yield attracted long-term investors, enhancing market confidence.
    
3.  On August 17, although analysts maintained a moderate buy rating on AbbVie, its high dividend and growth potential were still viewed positively.
    

Viking Therapeutics, up 5.28%, with a trading volume of $199 million. Based on recent key news:

1.  On August 19, Viking Therapeutics announced that its VK2735 achieved an average weight loss of 12.2% over 13 weeks, reaching both primary and secondary endpoints, leading to a 5.28% increase in stock price.
    
2.  On August 19, analysts expected VK2735's weight loss effect to be between 10% and 15%, and the actual results met expectations, prompting a positive market reaction.
    
3.  On August 20, analysts believed the market's reaction to VK2735 was excessive, with a minimum target price of $29, indicating a 20% upside potential for the stock price.
    

Gilead Sciences, up 1.67%, with a trading volume of $117 million. Based on recent important news:

1.  On August 15, Gilead Sciences' Chief Financial Officer Andrew D. Dickinson sold 2,500 shares of the company's common stock for a total of $296,325. This move may raise market concerns about insider confidence in the company, leading to stock price volatility.
    
2.  On August 19, analysts rated Gilead Sciences as a moderate buy but believed that five other stocks offered better investment value, which could affect investor confidence in Gilead.
    
3.  On August 20, overall market trading warmed up, with a booming stock market benefiting economic activity and investment sentiment, potentially driving Gilead Sciences' stock price up **Stocks Ranked Among the Top by Market Capitalization in the Industry**
    

Amgen rose 1.38%, with a market capitalization of $161.4 billion. Based on recent important news:

1.  On August 18, market analysis showed that although Amgen was rated as a hold, it was not included in the five stocks recommended by analysts, indicating a cautious attitude towards its future performance, yet the stock price still rose by 1.38%.
    
2.  On August 17, Amgen was not listed among the five stocks recommended by analysts; nevertheless, the market still recognized its hold rating relatively highly.
    
3.  On August 20, the overall market was active, with capital inflows driving the stock market up, and Amgen benefited from the improvement in overall market sentiment

### Related Stocks

- [VOR.US - Vor BioPharma](https://longbridge.com/en/quote/VOR.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 必和必拓利润飙升 30%，铜业务首次超越铁矿石成最大利润来源 | 全球市值最大的矿业公司必和必拓（BHP）因押注铜需求激增而获得回报，上半财年净利润同比增长近 30%。铜业务贡献了公司 51% 的基础息税折旧摊销前利润，首次超越其他业务成为最大利润来源。能源和汽车行业的强劲需求持续推高铜价，令这一转型的战 | [Link](https://longbridge.com/en/news/276092142.md) |
| 期权热点｜上周五 SILJ 大涨 5%，部分看涨期权飙升 103% | 美东时间 02 月 13 日， ETFMG 小市值银矿开采勘探 ETF -ETFMG 期权总成交 92131 张，看涨期权占比 89%，看跌期权占比 10%。 | [Link](https://longbridge.com/en/news/276030246.md) |
| 期权热点｜上周五 NBIS 大涨 9%，部分看涨期权飙升 378% | 美东时间 02 月 13 日，Nebius 期权总成交 179098 张，看涨期权占比 71%，看跌期权占比 28%。 | [Link](https://longbridge.com/en/news/276030151.md) |
| 宇树科技春晚节目技术难点解析 | 宇树科技在 2026 马年春晚中展示了全球首个全自主人形机器人集群武术表演《武 BOT》。该节目实现多项技术突破，包括连续花式翻桌跑酷、弹射空翻等。自 2025 年 11 月筹备以来，团队进行了基础软件开发、算法验证及实景测试，最终呈现出运 | [Link](https://longbridge.com/en/news/276089876.md) |
| 宇树机器人春晚武术表演再炸场，王兴兴：高动态高协同集群控制技术全球首秀 | 宇树科技创始人王兴兴表示，今年机器人的头部激光雷达、灵巧手等硬件和软件做了很多升级，“去年一整年，我们公司包括全中国的机器人的技术提升非常快，像我们公司的话，目前可以做各种的功夫动作，而且在舞台上面我们挑战了很多极限动作，可能一般的人，甚至 | [Link](https://longbridge.com/en/news/276086555.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.